Cargando…
2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and t...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051303/ https://www.ncbi.nlm.nih.gov/pubmed/35477193 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.10 |
_version_ | 1784696522727751680 |
---|---|
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes. |
format | Online Article Text |
id | pubmed-9051303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-90513032022-05-11 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 Zhongguo Fei Ai Za Zhi 病例报道 Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes. 中国肺癌杂志编辑部 2022-04-20 /pmc/articles/PMC9051303/ /pubmed/35477193 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.10 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 病例报道 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
title | 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
title_full | 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
title_fullStr | 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
title_full_unstemmed | 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
title_short | 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
title_sort | 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 |
topic | 病例报道 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051303/ https://www.ncbi.nlm.nih.gov/pubmed/35477193 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.10 |
work_keys_str_mv | AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào |